

2016-003291-47 – SUMMARY

A phase Ib/IIA clinical trial to combine the CSF1 receptor inhibitor pexidartinib with the androgen receptor antagonist enzalutamide in metastatic castration resistant prostate cancer

The justification for the early termination has arisen from the withdrawal of the drug company, at a late stage in trial set-up from contract finalisation. This has resulted in having no enzalutamide drug provision to conduct the trial.

As no drug was supplied, no sites have been activated and no patients have been recruited to treated under this protocol.

It is not planned to submit a study report as there are no data to report.

Early termination date 11 January 2019